Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GSK 
GlaxoSmithKline PLC ADR (GSK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: GSK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $47.11
1 Year Target Price $47.11
| 1 | Strong Buy |
| 0 | Buy |
| 5 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 4.14% | Avg. Invested days 41 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 94.09B USD | Price to earnings Ratio 13.42 | 1Y Target Price 47.11 |
Price to earnings Ratio 13.42 | 1Y Target Price 47.11 | ||
Volume (30-day avg) 8 | Beta 0.23 | 52 Weeks Range 30.68 - 47.16 | Updated Date 11/5/2025 |
52 Weeks Range 30.68 - 47.16 | Updated Date 11/5/2025 | ||
Dividends yield (FY) 3.61% | Basic EPS (TTM) 3.49 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-29 | When Before Market | Estimate 1.17 | Actual 1.4562 |
Profitability
Profit Margin 17.08% | Operating Margin (TTM) 32.61% |
Management Effectiveness
Return on Assets (TTM) 7.13% | Return on Equity (TTM) 41.52% |
Valuation
Trailing PE 13.42 | Forward PE 8.44 | Enterprise Value 107851166228 | Price to Sales(TTM) 2.93 |
Enterprise Value 107851166228 | Price to Sales(TTM) 2.93 | ||
Enterprise Value to Revenue 2.53 | Enterprise Value to EBITDA 9.29 | Shares Outstanding 2009592378 | Shares Floating 3891410820 |
Shares Outstanding 2009592378 | Shares Floating 3891410820 | ||
Percent Insiders 0.06 | Percent Institutions 19.16 |
Upturn AI SWOT
GlaxoSmithKline PLC ADR
Company Overview
History and Background
GlaxoSmithKline (GSK) was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham. Glaxo Wellcome evolved from Allen & Hanburys, founded in 1715. SmithKline Beecham traces its roots to a Philadelphia apothecary shop established in 1830. Significant milestones include the development of various vaccines and pharmaceuticals, and the company has evolved through strategic acquisitions and divestments.
Core Business Areas
- Pharmaceuticals: Focuses on researching, developing, and manufacturing innovative medicines, primarily in respiratory, HIV, oncology, and immunology.
- Vaccines: Develops and manufactures vaccines to prevent infectious diseases, including those for shingles, influenza, and childhood diseases.
Leadership and Structure
The CEO is Emma Walmsley. GSK operates with a board of directors and various executive teams overseeing different business segments and functions. The structure is designed to support its global research and development efforts and commercial operations.
Top Products and Market Share
Key Offerings
- Shingrix: A vaccine for shingles. It is a leading vaccine, capturing a significant market share. Competitors include Merck's Zostavax (discontinued) and potentially future vaccines.
- Duvroq: An antiviral HIV medication. This is a leader in the HIV market and generates substantial revenue. Competitors include Gilead Sciences, Viiv Healthcare.
- Trelegy Ellipta: A medication for COPD and asthma. This has increasing market share. Competitors include AstraZeneca and Boehringer Ingelheim.
Market Dynamics
Industry Overview
The pharmaceutical and vaccines industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. Innovation and patent protection are crucial for success.
Positioning
GSK is a major player in the global pharmaceutical and vaccines market. Its competitive advantages include its strong R&D pipeline, diverse portfolio of products, and global presence.
Total Addressable Market (TAM)
The global pharmaceuticals market is estimated to be worth over $1.4 trillion, and the vaccines market is valued at over $60 billion. GSK is positioned to capture a significant portion of these markets.
Upturn SWOT Analysis
Strengths
- Strong R&D capabilities
- Diverse product portfolio
- Global presence
- Strong brand recognition
Weaknesses
- Reliance on key products
- Exposure to patent expirations
- High R&D costs
- Dependence on successful drug launches
Opportunities
- Expanding into emerging markets
- Developing new vaccines and therapies
- Acquiring smaller biotech companies
- Growing demand for preventative healthcare
Threats
- Generic competition
- Regulatory changes
- Pricing pressures
- Economic downturns
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- MRK
- NVS
- ABBV
Competitive Landscape
GSK faces competition from large pharmaceutical companies with established portfolios and robust R&D pipelines. GSK's strength lies in vaccines and certain pharmaceutical areas, but it needs to continue innovating to maintain its market position.
Major Acquisitions
Affinivax
- Year: 2022
- Acquisition Price (USD millions): 2100
- Strategic Rationale: Acquired to bolster GSK's vaccine pipeline with innovative pneumococcal vaccine candidates.
Growth Trajectory and Initiatives
Historical Growth: Data not available for this tool.
Future Projections: Data not available for this tool.
Recent Initiatives: Recent initiatives include focusing on core business areas of pharmaceuticals and vaccines, investing in R&D, and divesting consumer healthcare assets.
Summary
GlaxoSmithKline is a major player in the pharmaceutical and vaccine industries, boasting a diverse portfolio and global presence. Its strong R&D capabilities and focus on key areas are positives; however, it needs to navigate generic competition, pricing pressures, and reliance on successful drug launches. Strategic acquisitions and expanding into emerging markets could enhance future growth. Monitoring regulatory changes and maintaining a robust pipeline are crucial.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and may vary across different sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GlaxoSmithKline PLC ADR
Exchange NYSE | Headquaters - | ||
IPO Launch date 1986-07-09 | CEO & Director Ms. Emma Natasha Walmsley | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 68629 | Website https://www.gsk.com |
Full time employees 68629 | Website https://www.gsk.com | ||
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.